Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Am J Nephrol ; 45(1): 49-59, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-27889746

RESUMO

BACKGROUND: Intravenous (IV) iron preparations are widely used in the treatment of anemia in patients undergoing hemodialysis (HD). All IV iron preparations carry a risk of causing hypersensitivity reactions. However, the pathophysiological mechanism is poorly understood. We hypothesize that a relevant number of these reactions are mediated by complement activation, resulting in a pseudo-anaphylactic clinical picture known as complement activation-related pseudo allergy (CARPA). METHODS: First, the in-vitro complement-activating capacity was determined for 5 commonly used IV iron preparations using functional complement assays for the 3 pathways. Additionally, the preparations were tested in an ex-vivo model using the whole blood of healthy volunteers and HD patients. Lastly, in-vivo complement activation was tested for one preparation in HD patients. RESULTS: In the in-vitro assays, iron dextran, and ferric carboxymaltose caused complement activation, which was only possible under alternative pathway conditions. Iron sucrose may interact with complement proteins, but did not activate complement in-vitro. In the ex-vivo assay, iron dextran significantly induced complement activation in the blood of healthy volunteers and HD patients. Furthermore, in the ex-vivo assay, ferric carboxymaltose and iron sucrose only caused significant complement activation in the blood of HD patients. No in-vitro or ex-vivo complement activation was found for ferumoxytol and iron isomaltoside. IV iron therapy with ferric carboxymaltose in HD patients did not lead to significant in-vivo complement activation. CONCLUSION: This study provides evidence that iron dextran and ferric carboxymaltose have complement-activating capacities in-vitro, and hypersensitivity reactions to these drugs could be CARPA-mediated.


Assuntos
Anemia Ferropriva/tratamento farmacológico , Ativação do Complemento/efeitos dos fármacos , Hematínicos/farmacologia , Compostos de Ferro/farmacologia , Falência Renal Crônica/terapia , Administração Intravenosa , Anemia Ferropriva/complicações , Complemento C1q/efeitos dos fármacos , Complemento C1q/metabolismo , Complemento C3d/efeitos dos fármacos , Complemento C3d/metabolismo , Complexo de Ataque à Membrana do Sistema Complemento/efeitos dos fármacos , Complexo de Ataque à Membrana do Sistema Complemento/metabolismo , Dissacarídeos/farmacologia , Dissacarídeos/uso terapêutico , Compostos Férricos/farmacologia , Compostos Férricos/uso terapêutico , Óxido de Ferro Sacarado , Óxido Ferroso-Férrico/farmacologia , Óxido Ferroso-Férrico/uso terapêutico , Ácido Glucárico/farmacologia , Ácido Glucárico/uso terapêutico , Hematínicos/uso terapêutico , Humanos , Técnicas In Vitro , Compostos de Ferro/uso terapêutico , Complexo Ferro-Dextran/farmacologia , Complexo Ferro-Dextran/uso terapêutico , Falência Renal Crônica/complicações , Maltose/análogos & derivados , Maltose/farmacologia , Maltose/uso terapêutico , Lectina de Ligação a Manose/efeitos dos fármacos , Lectina de Ligação a Manose/metabolismo , Properdina/efeitos dos fármacos , Properdina/metabolismo , Diálise Renal
2.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao ; 13(3): 195-8, 1991 Jun.
Artigo em Chinês | MEDLINE | ID: mdl-1652384

RESUMO

Sodium selenite exerts a marked inhibiting effect on the hemolysis induced by complement fixation. The results of rocket immunoelectrophoresis tests for the activated fragments C3d and C4d show that sodium selenite inhibits complement activation through the alternative pathway.


Assuntos
Ativação do Complemento/efeitos dos fármacos , Complemento C4b , Selênio/farmacologia , Complemento C3d/efeitos dos fármacos , Complemento C4/efeitos dos fármacos , Hemólise/efeitos dos fármacos , Humanos , Fragmentos de Peptídeos/efeitos dos fármacos , Selenito de Sódio
3.
Eur J Radiol ; 12(1): 63-6, 1991.
Artigo em Inglês | MEDLINE | ID: mdl-1999215

RESUMO

Four different radiographic contrast media (RCM) were used for i.v. urography in 40 patients, none of whom had complications. No rise in C3d was observed for any of the RCM, indicating that complement was not activated. However, significantly decreased values for CH50 were detected when the non-ionic RCM iopamidol and iohexol were used, and this may be due to interaction between the RCM and the complement molecules. Significantly increased numbers of neutrophils were observed in patients receiving ioxaglate, iohexol and diatrizoate, which may be due to inhibition of granulocyte adherence. No rise in the concentration of elastase and lactoferrin was observed. On the other hand, significantly decreased values of elastase were seen after injection of diatrizoate, which may be due to inhibition of the degranulation process by this media.


Assuntos
Proteínas do Sistema Complemento/efeitos dos fármacos , Meios de Contraste/farmacologia , Granulócitos/enzimologia , Urografia , Ativação do Complemento/efeitos dos fármacos , Complemento C3d/efeitos dos fármacos , Complemento C3d/metabolismo , Ensaio de Atividade Hemolítica de Complemento , Diatrizoato/farmacologia , Granulócitos/efeitos dos fármacos , Humanos , Iohexol/farmacologia , Iopamidol/farmacologia , Ácido Ioxáglico/farmacologia , Lactoferrina/metabolismo , Contagem de Leucócitos/efeitos dos fármacos , Neutrófilos/efeitos dos fármacos , Elastase Pancreática/metabolismo
4.
Ann Thorac Surg ; 49(2): 279-83, 1990 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-2306150

RESUMO

Complement activation is believed to be of importance in the development of complications arising after cardiopulmonary bypass. The effect on complement activation of priming the extracorporeal circuit with crystalloid alone, crystalloid plus albumin, or crystalloid plus the plasma expander polygeline was assessed in 36 patients undergoing coronary artery operations with cardiopulmonary bypass using a bubble oxygenator. Activation of the alternative and common complement pathways was monitored before, during, and after the bypass period by measuring concentrations of factor B and its fragment Ba and C3 and its fragment C3d. Complement activation occurred in all three groups of patients, with no difference between the crystalloid and crystalloid-albumin groups. In contrast, Ba fragment concentrations were persistently and significantly lower during and after bypass in the polygeline group, denoting reduced complement activation. C3d levels also showed a tendency to be lower in this group. Our results indicate that addition of polygeline to the priming solution reduces complement activation. Because complement activation is associated with morbidity after cardiopulmonary bypass, addition of polygeline to the priming solution may offer an inexpensive method of reducing morbidity after cardiopulmonary bypass.


Assuntos
Albuminas/farmacologia , Ponte Cardiopulmonar , Ativação do Complemento/efeitos dos fármacos , Soluções Isotônicas/farmacologia , Poligelina/farmacologia , Polímeros/farmacologia , Albuminas/administração & dosagem , Ponte Cardiopulmonar/métodos , Complemento C3/efeitos dos fármacos , Complemento C3b/análise , Complemento C3d/efeitos dos fármacos , Fator B do Complemento/análise , Feminino , Humanos , Soluções Isotônicas/administração & dosagem , Masculino , Pessoa de Meia-Idade , Fragmentos de Peptídeos/análise , Poligelina/administração & dosagem , Protaminas/farmacologia , Distribuição Aleatória , Lactato de Ringer
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...